Zecyte (Abiraterone)

Zecyte (Abiraterone) international name (abiraterone) is a new generation drug used in prostate cancer. The essence of the drug’s action is that it organizes the process of suppressing the enzyme CYP17, which is necessary for the biosynthesis of androgens. Androgens are hormones that are responsible for the development and maintenance of male sex characteristics. Androgens also promote tumor growth. In the treatment of androgen-sensitive prostate cancer, orchidectomy or luliberin agonists are used, but with these methods of treatment, a decrease in the synthesis of hormones only in the testes is noted, while Zecyte suppresses biosynthesis both in the testicles and in the adrenal glands and in the tumor itself, thereby inhibiting biosynthesis during All 3 sources. 1195 patients participated in studies of the effectiveness of Zecyte. Therapy with both abiraterone and prednisolone reduced the risk of mortality among patients by 35%, and overall survival increased by 3.9 months. In addition, the drug contributed to the reduction of pain symptoms in more respondents than in the placebo group. In case of prostate cancer, the drug “Zecyte” with the active ingredient abiraterone is excellent. It is able to fight the metastatic stage of castration-resistant pancreatic cancer, one of the most dangerous types of malignant tumors. Used together with prednisone. In case of prostate cancer, the drug “Zecyte” with the active ingredient abiraterone is excellent. It is able to fight the metastatic stage of castration-resistant pancreatic cancer, one of the most dangerous types of malignant tumors. Used together with prednisone. In case of prostate cancer, the drug “Zecyte” with the active ingredient abiraterone is excellent. It is able to fight the metastatic stage of castration-resistant pancreatic cancer, one of the most dangerous types of malignant tumors. Used together with prednisone.